Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective

Value in Health

Volumn 13, Issue 2, 2010, Pages 180-187

  Mernagh, Paul ^a   Suebwongpat, Arsupol ^a   Silverberg, Jay ^b   Weston, Adèle ^a,c  

^a Health Technology Analysts   (Australia)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cost effectiveness; Hypothyroid; RhTSH; Thyroid cancer

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROXINE;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG CLEARANCE; DRUG COST; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; MONEY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; THYROID CANCER;

EID: 77149173146     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00650.x     Document Type: Article

References (27)

1. Cooper DC, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 : 109 142.
2. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am 1995 24 : 803 839.
3. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 : 613 619.
4. LeClere J, Nunez S, Dejax C, et al. Quantitative and qualitative consequences of L-T4 suppressive withdrawal. European Association of Nuclear Medicine Congress, Abstract, Paris, 2000.
5. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 : 1147 1155.
6. Nijhuis TF, van Weperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschrift voor nucleaire geneeskunde 1999 21 : 98 100.
7. Kovatcheva RD, Hadjieva TD, Kirlov GC, Lozanov BS. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nucl Med Rev Cent East Eur 2004 7 : 13 19.
8. Luster M, Lippi F, Jarzab B, et al. rhTSH-Aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005 12 : 49 64. (Pubitemid 40477087)
9. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001 11 : 865 869.
10. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002 43 : 1482 1488.
11. 131I Administration in the Hypothyroid State : Final report 2 June 2004.
12. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international randomized controlled study. J Clin Endocrinol Metab 2006 91 : 926 932.
13. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokenetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003 30 : 1371 1377.
14. 131I. J Nucl Med 2003 44 : 1065 1068.
15. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002 25 : 44 52.
16. Borget I, Schlumberger M, Ricard M, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008 35 : 1457 1463.
17. Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006 155 : 405 414.
18. Caldwell CB, Ehrlich LE. Outpatient treatment of thyroid cancer using high doses of iodine 131. Can Assoc Radiol J 1999 50 : 331 336.
19. Brazier J, Underwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 1998 51 : 1115 1128.
20. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006 91 : 878 884.
21. Elisei R, Corone C, Driedger A, et al. Follow-up of differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after recombinant human thyrotropin (rhTSH) or thyroid hormone withdrawal. European Thyroid Association Conference, Germany September, 2007.
22. Tuttle MR, Brokhin M, Omrey G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008 49 : 764 770.
23. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokenetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006 46 : 648 654.
24. Links TP, van Tol KM, Plukker JTM, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 2005 12 : 273 280.
25. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996 10 : 460 466.
26. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 14 : 171 189.
27. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 146 : 473 481.